Form 4: Assembly Biosciences' Chief Scientific Officer Acquires Shares and Options

William E. Delaney IV, Chief Scientific Officer of Assembly Biosciences, reports acquisition of common stock and stock options.

Summary

• William E. Delaney IV, the Chief Scientific Officer of Assembly Biosciences, reported changes in beneficial ownership to the SEC.
• The report details the acquisition of common stock through the employee stock purchase plan and the grant of stock options.
• Delaney directly owns 16,733 shares of common stock.
• He was granted options to purchase 25,500 shares of common stock at an exercise price of $10.62, vesting over four years.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard insider transaction report. The acquisition of shares and options by an executive could be interpreted slightly positively, but it's a routine occurrence.

Positives

• The acquisition of shares and options by a key executive could be seen as a positive signal about the company's prospects.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for executives in the biotechnology industry.
• Vesting schedules of four years are typical for such grants.
• Comparing the size of the grant to those of executives at similar-sized biotech companies would provide further context.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Assembly Biosciences, insider trading, stock options, beneficial ownership, Form 4, Delaney, ASMB, Chief Scientific Officer